UBS Group Issues Pessimistic Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price

Harmony Biosciences (NASDAQ:HRMY – Free Report) had its price target lowered by UBS Group from $55.00 to $48.00 in a research note released on Monday, MarketBeat.com reports. UBS Group currently has a buy rating on the stock. A number of other equities analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on […]

Apr 29, 2025 - 08:30

Harmony Biosciences (NASDAQ:HRMY – Free Report) had its price target lowered by UBS Group from $55.00 to $48.00 in a research note released on Monday, MarketBeat.com reports. UBS Group currently has a buy rating on the stock. A number of other equities analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on […]